These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18781994)

  • 21. Early markers of cardiovascular risk in chronic kidney disease.
    Lai S; Dimko M; Galani A; Coppola B; Innico G; Frassetti N; Mazzei ED; Mariotti A
    Ren Fail; 2015 Mar; 37(2):254-61. PubMed ID: 25394527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin.
    May A; Wang TJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):793-804. PubMed ID: 18020909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on predictive biomarkers for major adverse cardiovascular events in patients undergoing vascular surgery.
    Patelis N; Kouvelos GN; Koutsoumpelis A; Moris D; Matsagkas MI; Arnaoutoglou E
    J Clin Anesth; 2016 Sep; 33():105-16. PubMed ID: 27555142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating soluble corin as a potential biomarker for cardiovascular diseases: A translational review.
    Yu R; Han X; Zhang X; Wang Y; Wang T
    Clin Chim Acta; 2018 Oct; 485():106-112. PubMed ID: 29944864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endostatin: a promising biomarker in the cardiovascular continuum?
    Ruge T; Carlsson AC; Larsson A; Ärnlöv J
    Biomark Med; 2017 Oct; 11(10):905-916. PubMed ID: 28976780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
    Smith JG; Gerszten RE
    Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury.
    Viereck J; Thum T
    Circ Res; 2017 Jan; 120(2):381-399. PubMed ID: 28104771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic biomarkers for predicting cardiovascular disease.
    Montgomery JE; Brown JR
    Vasc Health Risk Manag; 2013; 9():37-45. PubMed ID: 23386789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ozone exposure and systemic biomarkers: Evaluation of evidence for adverse cardiovascular health impacts.
    Goodman JE; Prueitt RL; Sax SN; Pizzurro DM; Lynch HN; Zu K; Venditti FJ
    Crit Rev Toxicol; 2015 May; 45(5):412-52. PubMed ID: 25959700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper.
    Biasucci LM; ;
    Circulation; 2004 Dec; 110(25):e560-7. PubMed ID: 15611382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations.
    Everett BM
    Trends Cardiovasc Med; 2017 Jan; 27(1):41-47. PubMed ID: 27422097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular biomarkers and sex: the case for women.
    Daniels LB; Maisel AS
    Nat Rev Cardiol; 2015 Oct; 12(10):588-96. PubMed ID: 26149486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antinuclear antibodies in the general population: positive association with inflammatory and vascular biomarkers but not traditional cardiovascular risk factors.
    Solow EB; Vongpatanasin W; Skaug B; Karp DR; Ayers C; de Lemos JA
    Clin Exp Rheumatol; 2018; 36(6):1031-1037. PubMed ID: 30299240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating cell-derived microparticles as biomarkers in cardiovascular disease.
    Thulin Å; Christersson C; Alfredsson J; Siegbahn A
    Biomark Med; 2016 Sep; 10(9):1009-22. PubMed ID: 27586235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper.
    Wilson PW; ;
    Circulation; 2004 Dec; 110(25):e568-71. PubMed ID: 15611383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction.
    Ge Y; Wang TJ
    Trends Cardiovasc Med; 2011 May; 21(4):105-12. PubMed ID: 22681965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application.
    Kim SH; Weiß C; Hoffmann U; Borggrefe M; Akin I; Behnes M
    Curr Pharm Biotechnol; 2017; 18(6):445-455. PubMed ID: 28571562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. suPAR: A New Biomarker for Cardiovascular Disease?
    Hodges GW; Bang CN; Wachtell K; Eugen-Olsen J; Jeppesen JL
    Can J Cardiol; 2015 Oct; 31(10):1293-302. PubMed ID: 26118447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing and assessing cardiovascular biomarkers.
    Dadu RT; Nambi V; Ballantyne CM
    Transl Res; 2012 Apr; 159(4):265-76. PubMed ID: 22424430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.